The UCW Newswire
  • MAIN
  • ABOUT
  • RSS FEED
  • CRYPTO NEWS
  • X
  • MCHATHIVE
Close
  • Home
  • Bio-Pharma
Category : Bio-Pharma
Alpenglow Biosciences and Mayo Clinic enter collaboration agreement to advance pathology and drug development through 3D spatial biology
Bio-Pharma Biotech Medical Venutre Capital
April 13, 2023

Alpenglow Biosciences and Mayo Clinic enter collaboration agreement to advance pathology and drug development through 3D spatial biology

Female-owned biotech startup, Tiamat Sciences raise an extension of $2M to accelerate product validation and strategic partnerships
Bio-Pharma Biotech Medical Startups Technology
March 9, 2023

Female-owned biotech startup, Tiamat Sciences raise an extension of $2M to accelerate product validation and strategic partnerships

Avicanna Announces Organizational Change in Avicanna LATAM S.A.S
Bio-Pharma Cannabis Medical Stock Market
December 30, 2022

Avicanna Announces Organizational Change in Avicanna LATAM S.A.S

Biomind Labs Announces the Completion of the First Sublingual Psychedelic Formulation for Its Drug Candidate BMND08 for Depression and Anxiety in Alzheimer’s Disease
Bio-Pharma Medical Technology
December 29, 2022

Biomind Labs Announces the Completion of the First Sublingual Psychedelic Formulation for Its Drug Candidate BMND08 for Depression and Anxiety in Alzheimer’s Disease

Optimi Health Appoints Principal Investigator for Clinical Dosing Study
Bio-Pharma Business Medical Stock Market
October 19, 2021

Optimi Health Appoints Principal Investigator for Clinical Dosing Study

ARCA biopharma Announces C. Jeff Dekker to be Appointed Chief Financial Officer
Bio-Pharma Stock Market
May 3, 2021

ARCA biopharma Announces C. Jeff Dekker to be Appointed Chief Financial Officer

Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage Development Plans in Parkinson’s Disease
Bio-Pharma Business Medical Stock Market Technology
May 2, 2021

Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage Development Plans in Parkinson’s Disease

Recent Posts

  • Despite High Rates, Leveraged Buyouts May Surge, Fueled by Innovation and Digital Asset-Backed Models
  • Walgreens Boots Alliance Shareholders Approve Acquisition by Sycamore Partners Management in Landmark Retail Shakeup
  • Legendary Eyes Lionsgate Acquisition Amid New Media’s Race for Content Supremacy
  • What If Netflix and AMC Joined Forces to Reinvent the Movie Theater Experience?
  • Wall Street’s Loyalty Test: Goldman and JPMorgan Demand Pledges from Junior Bankers, While Private Equity Backs Off
The UCW Newswire

Copyright UCW Newswire, All Rights Reserved